Peginterferon-α2a for the treatment of hepatitis B infection

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 8, 2005, Pages 1373-1380

  Graham, W ^a   Cooksley, E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adefovir; Chronic hepatitits B; Interferon; Lamivudine; Peginterferon a2a

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CLEVUDINE; CYTOCHROME P450; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; REMOFOVIR; TELBIVUDINE; TENOFOVIR; THEOPHYLLINE; UNCLASSIFIED DRUG; VIRUS DNA;

ALOPECIA; ANTIVIRAL ACTIVITY; ARTICLE; ASIA; CHRONIC HEPATITIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EUROPE; FATIGUE; FEVER; FOLLOW UP; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER DYSFUNCTION; MEDICAL DECISION MAKING; MONOTHERAPY; MYALGIA; NEUTROPENIA; NONHUMAN; PACIFIC ISLANDS; PHARMACODYNAMICS; SEROCONVERSION; SWITZERLAND; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT PLANNING; TURKEY (REPUBLIC); UNITED STATES;

HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS;

EID: 22744451231     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.8.1373     Document Type: Article

References (31)

1. MCMAHON BJ: The natural history of chronic hepatitis B virus infection. Semin. Liver Dis. (2004) 24(Suppl. 1): 17-21.
2. LOK AS, HEATHCOTE EJ, HOOFNAGLE JH: Management of hepatitis B: 2000. Summary of a workshop. Gastroenterology (2001) 120:1828-1853.
3. LOK AS, MCMAHON BJ: Chronic hepatitis B: update of recommendations. AASLD Practice Guideline. Hepatology (2004) 30:857-861.
4. THE EASL JURY: EASL International Consensus Conference on Hepatitis B, 13 - 14 September, 2002, Geneva, Switzerland. Consensus statement (short version). J. Hepatol. (2003) 38:533-540.
5. NO AUTHORS LISTED: EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J. Hepatol. (2003) 39(Suppl. 1):S3-S25.
6. LIAW Y-F, LEUNG N, GUAN R et al.: Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J. Gastroenterol. Hepatol. (2003) 18:239-245.
7. COOKSLEY WG: Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin. Liver Dis. (2004) 24(Suppl. 1):45-53.
8. WRIGHT TL: Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin. Liver Dis. (2004) 24(Suppl. 1):31-36.
9. TONG MJ, TU SS: Treatment of patients with chronic hepatitis B with adefovir dipivoxil. Semin. Liver Dis. (2004) 24(Suppl. 1):37-44.
10. MARCELLIN P, CHANG TT, LIM S et al.: Long term efficacy and safety of adefovir dipivoxil (ADV) 10mg in HBeAg positive chronic hepatitis B patients: increasing serologic, virologic and biochemical response over time. Hepatology (2004) 40(Suppl. 1):655A.
11. CHANG TT, GISH R, DE MAN R et al.: Entecavir is superior to lamivudine for the treatment of HBeAg + chronic Hepatitis B: results of Phase III study ETV-022 in nucleoside naüive patients. Hepatology (2004) 40(Suppl. 1):193A.
12. LAI CL: New antiviral agents for chronic hepatitis B. Antiviral Ther. (2004) 9:H9.
13. FRIED MW, SHIFFMAN ML, REDDY KR et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. (2002) 347:975-982.
14. PERRY CM, JARVIS B: PEG interferon alfa 2-a (40 KD): a review of its use in the management of chronic hepatitis C. Drugs (2001) 61:2263-2288.
15. SCOTT LJ, PERRY CM: Interferon alfa 2-b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs (2002) 62:507-556.
16. KEATING GM, CURRAN MP: PEG interferon alfa 2-a (40 KD) plus ribavirin. A review of its use in the management of chronic hepatitis C. Drugs (2003) 63:701-730.
17. MARTIN NE, SY S, MODI M: The enhanced efficacy of PEG (40 KD) IFN alfa 2-a (Pegasus) in chronic hepatitis C (CHC) may be explained by the optimisation of the pharmacokinetics (PK) of interferon (IFN) by a branched methoxy 40 KD polyethylene glycol (PEG) moiety. Ninth International Congress on Infectious Diseases. Buenos Aires, Argentina (10 - 13 April 2000).
18. MARTIN P, MITRA S, FARRINGTON K et al.: Pegylated (40 KD) interferon alfa 2-a (Pegasys) is unaffected by renal impairment. Hepatology (2000) 32:370A.
19. SY S, MARTIN NE, PATEL IH et al.: Drug interactions between PEG (40 KD)-IFN alfa 2-a (PEGASYS) and cytochrome P450 (CYP 450)-metabolised drugs are unlikely except to those metabolised by CYP 1A2. Ninth International Congress on Infectious Diseases. Buenos Aires, Argentina (10 - 13 April 2000).
20. COOKSLEY WG, LAI M-Y, PIRATVISUTH T et al.: Peginterferon α-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. (2003) 10:298-305.
21. COOKSLEY WG, LAI M-Y, PIRATVISUTH T et al.: Treatment with peginterferon alfa-2a (40kD) (Pegasys) results in improved rates of response compared to conventional interferon in patients with HBeAg positive chronic hepatitis B, including HBV genotypes B or 'difficult to treat' genotype C. J. Hepatol. (2003) 38:52.
22. LAU GKK, PIRATVISUTH T, LUO KX et al.: Peginterferon alfa-2a as monotherapy and in combination with lamivudine monotherapy in patients with HBeAg positive chronic hepatitis B. Hepatology (2004) 38(Suppl. 1):171A.
23. MARCELLIN P, LAU GK, BONINO F et al.: Peginterferon alfa-2A alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2004) 351:1206-1217.
24. BRUNETTO MR, OLIVERI F, COCO B et al.: The outcome of chronic anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J. Hepatol. (2002) 36:263-270.
25. MANESIS EK, HADZIYANNIS SJ: Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology (2001) 121:101-109.
26. LAMPERTICO P, DEL NINNO E, MANZIN A et al.: A randomized controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology (1997) 26:1621-1625.
27. PAPATHEODORIDIS GV, MANESIS E, HADZIYANNIS SJ: The long term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J. Hepatol. (2001) 34:306-313.
28. SCHALM SW, HEATHCOTE J, CIANCIARA J et al.: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. For the International Lamivudine Study Group. Gut (2000) 46:562-568.
29. JANSSEN HLA, VAN ZONNEVELD M, SENTURK H et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 365:123-129.
30. THOMAS HC, LOK AS, CARRENO V et al.: Comparative study of three doses of interferon alfa 2-a in chronic active hepatitis B. J. Viral Hepat. (1994) 1:139-148.
31. NIEDERAU C, HEINTGES T LANGE S et al: Long term follow up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. (1996) 334:1422-1427.